Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Major contract win

16 May 2014 12:25

RNS Number : 3595H
Venn Life Sciences Holdings PLC
16 May 2014
 



Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Major contract win

 

Venn Life Sciences Signs Master Service Agreement for Multi-Country Study

Value is in excess of €3m covering 8 countries in Europe & North America over 18 months

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the securing of a multi-country multi-million euro clinical trials management agreement with a major European biotechnology company.

 

This multi-site agreement will run for over a year and a half, covering seven European countries as well as a number of US sites and is valued in excess of €3m. The clinical trial management programme is for an orphan drug in a rare acute disease area and is proceeding this month.

 

Over the past year Venn has increased its geographic footprint in Europe with new offices in the UK and Germany. Business development has been focused on key growth areas of drug and device development and on winning similar studies across Europe, with a solid pipeline of work for 2014 and 2015 now secured. Studies in rare diseases have increased significantly in recent years and Venn has invested in ensuring they have the critical multi-site agile service capabilities essential to conduct and manage trials efficiently in this sector.

 

Commenting, Venn CEO, Tony Richardson, said:

"We are hearing from many of our clients - in the key pharmaceutical, biotechnology and medical device sectors - of a growing need for a much more agile multi-country clinical trial management capability, especially in the still complex greater European region. Venn has invested heavily in 2013 in preparing the business for a step change in the size and complexity of contracts undertaken. This contract win, and our current pipeline, represent a significant endorsement of our investment strategy since IPO. We have now moved our business focus from small single country projects to larger multicentred projects and we expect to cement this progress with additional project wins in the coming months."

 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager

Tel: +33 (0)1 30 82 67 07

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - innoVenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBBGDUSDBBGSL
Date   Source Headline
11th Mar 20217:00 amRNSJournal for Clinical Studies article publication
9th Mar 20217:00 amRNSNew contract win with Oxford BioTherapeutics
26th Feb 20214:58 pmRNSHolding(s) in Company
17th Feb 20219:00 amRNSEthics approval - COVID-19 Human Challenge Study
9th Feb 20213:57 pmRNSHolding(s) in Company
3rd Feb 20217:05 amRNSExercise of Investor Warrants & TVR
3rd Feb 20217:00 amRNSNew challenge study quarantine clinic
1st Feb 20217:00 amRNSContract extension with Carna Biosciences
21st Jan 20217:00 amRNSArticle published in Drug Discovery Today
20th Jan 20217:00 amRNSExpansion of volunteer recruitment centres
11th Jan 20217:00 amRNSFirst volunteer dosed in COVID-19 clinical trial
6th Jan 20214:29 pmRNSHolding(s) in Company
6th Jan 20217:00 amRNSContract renewal with top-3 pharmaceutical client
31st Dec 20207:00 amRNSRule 19.6(c) Confirmation
23rd Dec 20207:00 amRNSSuccessful completion of toxicology study
22nd Dec 20207:00 amRNSContract renewal with top-3 pharmaceutical client
14th Dec 20207:30 amRNSExercise of Share Options
14th Dec 20207:00 amRNSMHRA approval for nasal COVID-19 vaccine trial
7th Dec 20207:00 amRNSVenn Life Sciences contract wins
24th Nov 20207:00 amRNSDirectors Change
19th Nov 20207:00 amRNSCollaboration with HIC-VAC and Wellcome Trust
5th Nov 20207:00 amRNSNew £2.5m Influenza Challenge Study Contract Win
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:10 amRNSExercise of Share Options
30th Oct 20207:00 amRNSNew 2-year contract with a tier 1 German company
20th Oct 20207:00 amRNSContract Signed with UK Government
16th Oct 20208:47 amRNSStatement re further media comment
30th Sep 20207:00 amRNSInterim Results for 6 months ended 30 June 2020
28th Sep 20207:00 amRNSNew £4.3m Challenge Study Contract Win
24th Sep 20207:00 amRNSStatement re price movement and press speculation
23rd Sep 20204:41 pmRNSSecond Price Monitoring Extn
23rd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20207:30 amRNSExercise of Investor Warrants and Issue of Shares
22nd Sep 20207:00 amRNSNew Contract Win
7th Sep 20207:00 amRNShVIVO present at 2020 ERS International Congress
10th Aug 20207:00 amRNSMajor New Contract Win with Top 3 Pharma Company
4th Aug 20207:00 amRNSNew Contract Win with Carna Bioscience ("Carna")
28th Jul 20207:00 amRNSContract for COVID-19 Vaccine Trial
22nd Jul 202012:43 pmRNSResult of AGM
15th Jul 20207:00 amRNSOption to Acquire CHIMagents Limited
10th Jul 20208:00 amRNSEuronext Growth Dublin Notice
8th Jul 20207:00 amRNSUpcoming Investor Events
7th Jul 20207:10 amRNSExercise of Warrants
7th Jul 20207:00 amRNSAdditional Laboratory Services Contracts Signed
26th Jun 20201:05 pmRNSNotice of AGM
24th Jun 20207:00 amRNSResults for the year ended 31 December 2019
17th Jun 20209:33 amEQSHardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020
15th Jun 20207:00 amRNSPositive Phase I results published in The Lancet
12th Jun 20208:00 amRNSEuronext Growth Dublin Notice
11th Jun 202012:15 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.